Quantcast
NASA Study Investigates Impact Of Prolonged Spaceflight On

NASA Study Investigates Impact Of Prolonged Spaceflight On The Immune System

redOrbit Staff & Wire Reports - Your Universe Online Newly discovered changes to the human immune system that occur during spaceflight could force NASA to address potential health concerns in future six-month to one-year-long manned...

Latest Autoimmunity Stories

2014-08-14 12:28:37

Expert from the Largest Scleroderma Specialty Center in the U.S. at Johns Hopkins will Provide Insight to Help Patients, Physicians and Caregivers. SAN FRANCISCO, Aug. 14, 2014 /PRNewswire-USNewswire/ -- Dr. Francisco Boin of the Scleroderma Center at The Johns Hopkins University School of Medicine, one of the largest scleroderma specialty clinics in the world, will host a live, free webinar on Thursday, August 21, 2014 at 1:00 p.m. EDT. The webinar is presented by the Scleroderma...

parasitic worms
2014-08-12 03:00:09

Monash University Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. The Monash University study, published in the FASEB Journal, successfully identified peptides from parasitic worms that suppress the body’s immune response. Researchers believe this could pave the way for a new drug containing the peptide to provide relief...

2014-07-30 04:21:20

CAMBRIDGE, Mass. and HERZLIYA PITUACH, Israel, July 30, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company") announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid. This open-label trial will enroll 10-15 patients who will receive two...

2014-07-24 04:21:22

NEW YORK, July 24, 2014 /PRNewswire/ -- Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company"), announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties. Lyfebulb is a health and wellness company dedicated...

2014-07-21 12:24:51

DANVERS, Mass., July 21, 2014 /PRNewswire/ -- The Scleroderma Foundation is preparing for 600 people from around the world to attend its National Patient Education Conference later this week in Southern California. This unique educational event will be held at the Anaheim Marriot Friday, July 25, through Sunday, July 27. The conference focuses on scleroderma, a mysterious, and sometimes fatal, autoimmune disease that causes a person's body to attack itself by creating too much...

2014-07-18 23:02:00

Annual conference provides groundbreaking approaches to treating patients with interrelated autoimmune conditions. Malvern, PA (PRWEB) July 18, 2014 The inaugural Interdisciplinary Autoimmune Summit (IAS) brought together more than 150 gastroenterologists, rheumatologists, dermatologists, immunologists, internists, industry, and other allied healthcare professionals at The Mirage, Las Vegas, NV, June 20-22, 2014. "IAS 2014 was a wonderful opportunity to meet and discuss best...

2014-07-16 08:29:40

HERZLIYA, Israel, July 16, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that an overview of its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE) is included in an article titled, Novel Approaches to the Development of...

2014-07-16 08:28:17

PORTLAND, Ore., July 16, 2014 /PRNewswire-USNewswire/ -- Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis--an autoimmune disease that appears on the skin, affecting 7.5 million Americans--and psoriatic arthritis--an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis. Learn more about the NPF research...

2014-07-16 08:28:09

--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE). http://photos.prnewswire.com/prnvar/20140715/127341 Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients. The...

2014-07-15 00:20:40

SAN DIEGO, July 14, 2014 /PRNewswire/ -- aTyr Pharma, an innovative rare disease therapeutics enterprise announced today, the scientific publication of a splice variant of a tRNA synthetase in association with a rare muscle disease. This article, published in the Journal of Biological Chemistry, demonstrated novel findings relative to Physiocrine proteins, that include extracellular functions derived from the tRNA synthetase gene family. These data further highlight the potential...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related